Symbiotec Pharmalab Ltd’s initial public offering (IPO) had received cumulative bids for 91,68,240 shares against the total offer size of 1,31,24,929 shares by 3.30 PM on day one, translating to an overall subscription of 0.70 times. The IPO is open for subscription from August 24 to August 27.
The ₹1,757 crore issue, priced at ₹938–988 per share, comprises a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore. The offer for sale is being conducted by promoter Satwani Holdings LLP and public shareholders Rosewood Investments and India Business Excellence Fund III.
Among investor categories, the employee reservation portion led with 1.19 times subscription. Non-Institutional Investors (NII) in the sub-₹10 lakh bracket were the only open-market category to cross full subscription at 1.33 times. Retail Individual Investors stood at 0.82 times, while the broader NII category was at 0.86 times. Qualified Institutional Buyers (QIB) remained the weakest segment at 0.35 times, with Foreign Institutional Investors accounting for 2,90,685 of the 13,18,410 QIB bids received so far.
Copyright© 2026, THG PUBLISHING PVT LTD. or its affiliated companies. All rights reserved.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
Source: Read the original article on www.thehindubusinessline.com
